C-JWVPImmunis
stem cell-derived secretome, multi-active biologics, regenerative factors
modulatingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-JWVP
C-JWVPC-JWVPstem cell-derived secretome, multi-active biologics, regenerative factors
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Placebo controlled study for safety and efficacy of IMM01-STEM on muscle performance in seniors with obesity and muscle weakness
An open-label dose escalation study to assess the safety and tolerability of IMM01-STEM in participants with muscle atrophy related to knee osteoarthritis
The expanded access is designed for patients requesting the treatment, and whose medical condition may benefit from treatment, but are unable to participate in any other IMM01-STEM clinical trial in their physician's opinion for reasons that include: (1) They do not meet enrollment criteria, or (2) They cannot perform the assessment of outcomes, or (3) The trial site is not geographically accessible.
Stock and Other Ownership Interests - AIVITA Biomedical, Inc. Consulting or Advisory Role - Immunis.AI; Regeneration Biomedical.
Immunis, Inc., a clinical-stage biotechnology company, has ... American Society of Clinical Oncology (ASCO) ASHP European Society ...
AZD3470 at ASCO 2026: a promising new drug for Hodgkin lymphoma? ... Immunis receives FDA clearance for Phase II sarcopenic obesity therapy trial.
Research Funding - Immunis.AI; Myriad Pharmaceuticals; pathnostics. Zachary Alan Gerndt. Employment - comprehensive urology. Nathan Shen. Employment ...
12-14, 2026 SAN FRANCISCO, CA Hans Keirstead Immunis, Inc. ... 12-14, 2026 SAN FRANCISCO, CA Hans Keirstead Immunis, Inc. ... AACR ANNUAL MEETING 2026 WHOLE- ...
The mission of the American Association for Cancer Research (AACR) is to ... Immunis.AI ImmunityBio. Immunizeca Immunocore Immunologic Immunome
American Association for Cancer Research Logo Open Menu ... Immunis e.V.; 6Institute of Pathology, Academic ... AACR Journals on Social Media.
Immunis has closed a $10M series A first closing financing for ... AACR 2026: where is cancer therapeutics heading? Drug Development.
OR immuniz* OR immunis* OR shot* OR jab OR jabs) AND (Intent* OR willing* OR ... Hoeven M, Smit GSA. Worldwide vaccination willing- ness for COVID-19 ...
Skip to main content Hogy küzdj a Pumpkinless Arisennel GSA ... Hogy küzdj a Pumpkinless Arisennel GSA-ként? ... Immunis a végzetre és összezavarodott. u/ ...
Hearing about Alberta's potential to build a new economy in the tech sector was truly inspiring. At Immunis Financial Brokers Inc., we're proud to support this ...
limosus (5.0%) and O immunis (1.0 %). Non-native crayfish are suspected ... © Copyright 2009 The Geological Society of America (GSA), all rights reserved.
immunis]) would affect leopard frog oc ... 4). Models for leopard frog breeding yielded similar re sults, although a larger number of models were within. 2 AAIC ...
... Alzheimer's Association International Conference 2015 (AAIC 2015) in Washington, D.C. ... Immunis plans Phase 1 trial of treatment for ...
Rejuvenation Startup Summit 2024 announces first set of speakers ... Keirstead, Chairman of the Board of Immunis Inc. – developing immune ...
For additional information about the Rejuvenation Startup Summit please visit: www.forever-healthy.org/summit/. About Immunis Inc. Immunis is ...
Every year the movers and shakers of the life science industry present at the Annual J.P. Morgan Healthcare Conference. ... Immunis, Inc. 1 ...
Immunis CEO Hans Keirstead explains why his company thinks the immune system ... The JP Morgan Healthcare Conference is seen as a barometer for the ...
BIO International Convention. Home. Immunis Inc is a private biotechnology company developing a novel immunomodulatory secretome product for the various ...
The BIO International Convention represents the largest global event for biotech, offering networking, partnership opportunities, ...
About BIO International Convention · Venue · Future dates · Attendee Policies ... Immunis, Inc. Visit website · View all 2025 Presenting Companies · ImmuneWalk ...
The BIO International Convention represents the largest global event for biotech, offering networking, partnership opportunities, ...
... Immunis) covered the following topics: unlocking the secrets of ... Vitalist Bay 2026 set to spotlight longevity's next phase · J Craig ...
Immunis, Inc. Infinita City. InnovateBio - National Biotechnology Education ... Vitalist Bay. Viva City. Vivex Biologics. Vycellix. Wake Forest Institute ...
... Immunis Dr. Hans Keirstead, Chairman, Immunis ... Oki will break down what genuine disease-modifying medicine looks like at Vitalist Bay ...
Hans Keirstead, is an invited speaker at the exclusive Longevity Investors Lunch in Davos, Switzerland (hosted by Longevity Investors Conference) ...
Our portfolio company, Immunis, announced the first-in-human injection of its stem cell secretome product to treat age and disease-related immune decline ...
... (RAADfest) 2022. QUADSMaster. September 20, 2022 ... September 13, 2022. Immunis Signs Clinical Trial Agreement with CIRM Alpha Stem Cell Clinics. QUADSMaster.
quadraScope's presentation at RAADfest 2022 · QUADSMaster · October 10, 2022 ... Immunis Signs Clinical Trial Agreement with CIRM Alpha Stem Cell Clinics ...
Immunis: Targets immune system aging. Samsara Therapeutics: Engages in ... (ARDD) 2024, further solidifying its commitment to advancing research in ...
... Immunis' secretome product on muscle growth, metabolism, and inflammation in aged miceEarly results from Immunis' Phase 1/2a clinical trial in older adults ...
The 9th ARDD: Longevity Biotechnology Is Gaining Prominence and Credibility in the Pharmaceutical Industry · admin · August 11, 2022. Portfolio: Immunis ...
Chairman, SAB Immunis Biomedical, Inc. · Experience: Immunis Biomedical, Inc. · Location: Laguna Beach · 242 connections on LinkedIn. View Robert Cockrell ...
We invite you to learn about how Dr. Keirstead approaches this delicate research and how companies like Immunis are aiming to use stem cell-derived secretomes ...
Dr. Diamandis' books, blogs, podcasts and webinars educate millions of individuals regularly. Immunis is honored to have such an innovative ...
Immunis' investigational therapy, IMM01-STEM, is a stem cell-derived secretome designed to modulate immune health and improve muscle mass and ...
Discover how Immunis's groundbreaking approach to aging therapeutics is unlocking the secrets to longevity. Experts like Dr. Hans Keirstead, ...
Daniel Kraft, M.D. - Board Member at Immunis.
... podcast episode to describe the surprising connection between immune function and muscle health. Tune in to learn why Immunis has bet big on ...
In this episode, Chris and Hans discuss Immunis' approach to targeting the aging immune system as a key driver of age-related disease. They ...
Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related ...
Immunis has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase I ...
Immunis, Inc., a private biotech company developing an innovative treatment for age and disease-related immune decline, announces its ...
Immunis is a clinical-stage biotechnology company developing multi-active stem cell-derived biologics for the various manifestations of age-related diseases and ...
Immunis is a private biotechnology company developing a novel immunomodulatory stem cell-derived biologic for the various manifestations of age ...
Immunis is a clinical-stage biotechnology company developing multi-active biologics for the various manifestations of age-related diseases and ...
Immunis, Inc., a clinical-stage biotech developing novel secretomes for age-related diseases and immune dysfunction, has initiated non-terminal safety studies ...
Immunis has developed a cell-derived secretome technology that is beneficial to the health of the immune system development.
Immunis is a private biotechnology company targeting age-driven diseases and immune dysfunction. Our team developed a novel method to isolate clinical-grade, ...
Discover how Immunis, a private biotechnology company is developing new secretome products for the treatment of age-related immune dysfunction.
Charlie Kim, PhD. Strategic Advisor Read More. Andrea Lucard. Strategic Advisor ... Immunis, AIVITA. Neema Mgana, PhD. United Nations. Rey Ramsey. CEO, Nathan ...
... Charlie Kim, PhD · Charlie Kim, Ph.D. Advisory Board Member Chief Scientific Officer Tesorai. Recent News. Mar 5, 2026. Immunis Licenses Treatment Candidate for ...